|Day's Range||4.57 - 4.72|
|52 Week Range||2.35 - 4.84|
|PE Ratio (TTM)||-5.28|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.18|
NASDAQ: CRME TSX: COM VANCOUVER , July 17, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that the Therapeutic Products Directorate (TPD) of Health Canada has approved ...
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).